Commentary on: Chou AIW, Wang Y-C, Lin C-L, et al. Female schizophrenia patients and risk of breast cancer: a population-based cohort study. Schizophrenia Research 2017;188:165–171.
What is already known on this topic
Research into rates of breast cancer in women with schizophrenia shows conflicting results, with reports of increased, decreased and the same risk as the general population. This is despite women with schizophrenia possibly being at increased risk of breast cancer through use of antipsychotic medications, many of which increase prolactin, a hormone involved in cellular differentiation of the mammary glands. This study1 investigated rates of breast cancer in individuals with schizophrenia compared with the general population.. To read the full article, log in using your NHS OpenAthens details.
Commentary on: Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 2017;74:686–693.
What is already known on this topic
It is essential to identify differences in efficacy and effectiveness between antipsychotic options to inform treatment decisions in schizophrenia. Presence or absence of superiority has recently been particularly controversial for clozapine and long-acting injectable antipsychotics (LAIs), triggered by contrasting positive, negative and inconsistent meta-analyses of randomised controlled trials (RCTs).1–4 These inconsistencies may have been largely the result of selection bias since patients enrolled in RCTs may have a less severe illness, more insight, greater adherence and an overall better prognosis.4 This selection bias may be particularly important for clozapine and LAIs, which may be most effective in treatment-resistant patients and those with greater likelihood of non-adherence-related poor outcomes.. To read the full article, log in using your NHS OpenAthens details.
Commentary on : Bergman H, Walker DM, Nikolakopoulou A, et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017;21:1-218.
What is already known on this topic
Tardive dyskinesia (TD) is a relatively frequent side effect of long-term use of antipsychotics and there is conflicting evidence if the incidence of TD is lower with second-generation antipsychotics (excluding clozapine), compared with first-generation antipsychotics. Until now there is no evidence-based algorithm to prevent or to treat TD.
Open access. It is time that all patients with acute-onset psychosis are screened for autoimmune encephalitis, that lumbar puncture becomes a routine psychiatric investigation and that immunotherapy is available in indicated cases. We call for a culture change in the management of psychosis by psychiatry.
It is important that nurses who work with individuals experiencing Serious Mental Illness (SMI) understand the assessment and management of specific communication, speech and language needs. You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
A nursing student reflects on the profound effect of taking time to share a meal with a patient with schizophrenia. You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
The presence of psychosis in Alzheimer’s disease denotes a phenotype with more rapid cognitive deterioration than in Alzheimer’s disease without psychosis. Discovery of novel pharmacotherapies that engage therapeutic targets for prevention or treatment of Alzheimer’s disease with psychosis would benefit from identifying the neurobiology of resilience to psychosis in Alzheimer’s disease. The primary objective of this study was to determine whether alterations in the synaptic proteome were associated with resilience to psychotic symptoms in Alzheimer’s disease and, if present, were independent of neuropathologic burden.. Login at top right hand side of page using your MPFT NHS OpenAthens for full text. SSOTP (legacy account)- Please contact the library to receive a copy of this article - http://bit.ly/1Xyazai
For people with schizophrenia treated with antipsychotic therapy, adjunct valproate may lead to more people having a clinically significant response and a slightly better mental state.
Acutely occurring, life-threatening side-effects of antipsychotic drugs might contribute to the reduced life expectancy observed in patients with severe mental disorders. We aimed to assess this hypothesis by doing a systematic review and meta-analysis of deaths occurring in placebo-controlled trials of antipsychotic drugs.. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Comment. Second-generation antipsychotic medications such as aripiprazole, olanzapine, quetipaine, and risperidone are widely used for the treatment of psychotic disorders and other psychiatric conditions. Concerns have been raised as to their role in patients' mortality. In this issue of The Lancet Psychiatry, Johannes Schneider-Thoma and colleagues report on a systematic review and meta-analysis of the mortality outcomes in randomised, placebo-controlled trials of second-generation anti-psychotics.1 The authors conclude that there is no evidence that second-generation antipsychotics are associated with an overall increase in mortality when all clinical populations are considered. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai